XORTX regains Nasdaq compliance after reverse stock split

XORTX Therapeutics Inc. (NASDAQ: XRTX) announced it has received a compliance letter from Nasdaq confirming it has met the exchange's minimum bid price requirement of $1.00 per share.

The pharmaceutical company implemented a 1-for-5 reverse stock split on April 6, 2026, which allowed its shares to trade above the required $1.00 threshold for 10 consecutive trading days. The company met this requirement on April 17, 2026, and received the compliance letter from Nasdaq on April 20, 2026.

The compliance resolves a deficiency related to Nasdaq Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of $1.00 per share. Companies that fall below this threshold must regain compliance within a specified timeframe to avoid delisting.

XORTX develops treatments for gout and progressive kidney disease. The company has three programs in clinical development: XRx-026 for gout treatment, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney injury associated with respiratory virus infections.

The company also trades on the TSX Venture Exchange under the symbol XRTX and on the Frankfurt Stock Exchange under ANU. XORTX is based in Calgary, Alberta.

You May Also Be Interested In

• Muddy Waters Research is short The Ensign Group (ENSG)
• Spacex IPO Retail Orders Are Said To Increase To Over $100b - Bloomberg
• NYC Council Speaker Julie Menin Receives Auschwitz Jewish Center Foundation’s Fighting Hatred Award